Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-04-22
2008-04-22
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
10893712
ABSTRACT:
The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic adds contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
REFERENCES:
patent: 6001613 (1999-12-01), Donis et al.
patent: 2004/0081666 (2004-04-01), Dominowski
patent: WO2004/017990 (2004-03-01), None
patent: WO2004/093904 (2004-11-01), None
Becher et al., “Cytopathogenicity of Border Disease Virus Is Correlated with Integration of Cellular Sequences into the Viral Genome,” Journal of Virology, vol. 70, No. 5 (1996).
Becher et al., “Ribosomal 27a Coding Sequences Upstream of Ubiquitin Coding Sequences in the Genome of a Pestivirus,” Journal of Virology, vol. 72, No. 11 (1998), pp. 8697-8704.
Endsley et al., “Maternal antibody blocks humoral but not T cell responses to BVDV,” Biologicals 31, pp. 123-125 (2003).
Endsley et al., “Bovine Viral Diarrhea Virus Type 1- and Type 2-Sepcific Bovine T lymphocyte-Subset responses Following Modified-Live Virus Vaccination,” Veterinary Therapeutics vol. 3, No. 4 (2002), pp. 364-372.
Fulton et al., “Antibody responses by cattle after vaccination with commercial viral vaccines containing bovine herpesvirus-1, bovine viral diarrhea virus, parainfluenza-3 virus, and bovine respiratory syncytial virus imunogens and subsequent revaccination at day 140,” Vaccine vol. 13, No. 8 (1995) pp. 725-733.
Mendez et al., “Infectious Bovine Viral Diarrhea Virus (Strain NADL) RNA from Stable cDNA clones: a Cellular Insert Determines NS3 Production and Viral Cytopathogenicity,” Journal of Virology, vol. 72, No. 6, (1998), pp. 4737-4745.
Scherer et al., “Experimental infection of pregnant ewes with bovine viral diarrhea virus type-2 (BVDV-2): effects on the pregnancy and fetus,” Veterinary Microbiology 79, pp. 285-299 (2001).
Willson et al., “Tissue Reaction and Immunity in Swine Immunized withActinobacillus pleuropneumoniaeVaccines,” Can. J Vet REs 59: 299-305 (1995).
Martina Baroth, et. al., “Insertion of Cellular NEDD8 Coding Sequences in Pestivirus”,Virology, vol. 278, pp. 456-466, (2000).
Paul Becher, et. al., “Nonhomologous RNA Recombination in Bovine Viral Diarrhea Virus: Molecular Characterization of a Variety of Subgenomic RNAs Isolated during an Outbreak of Fatal Mucosal Disease”,Journal of Virology, vol. 73, No. 7, pp. 5646-5653, (1999).
Paul Becher, et. al., “RNA Recombination between Persisting Pestivirus and a Vaccine Strain: Generation of Cytopathogenic Virus and Induction of Lethal Disease”,Journal of Virology, vol. 75, No. 14, pp. 6256-6264, (2001).
N. Cammack, et. al., “Intertypic Genomic Rearrangements of Poliovirus Strains in Vaccinees”,Virology, vol. 167, pp. 507-514, (1988).
Milena Furione, et. al., “Polioviruses with Natural Recombinant Genomes Isolated from Vaccine-Associated Paralytic Poliomyelitis”,Virology, vol. 196, pp. 199-208, (1993).
Maria-Magdalena Georgescu, et. al., “High Diversity of Poliovirus Strains Isolated from the Central Nervous System from Patients with Vaccine-Associated Paralytic Poliomyelitis”,Journal of Virology, vol. 68, No. 12, pp. 8089-8101, (1994).
M.-J. Kim, et. al., “Factors regulating template switch in vitro by viral RNA-dependent RNA polymerases: Implications for RNA-RNA recombination”,PNAS, vol. 98, No. 9, pp. 4972-4977, (2001).
Galina Y. Lipskaya, et. al., “Frequent Isolation of Intertypic Poliovirus Recombinants With Serotype 2 Specificity From Vaccine-Associated Polio Cases”,Journal of Medical Virology, vol. 35, pp. 290-296, (1991).
Gregor Meyers, et. al., “Molecular Characterization of Pestiviruses”,Advances in Virus Research, vol. 47, pp. 53-118, (1996).
John D. Neill, et. al., “Recombination with a cellular mRNA encoding a novel DnaJ protein results in biotype conversion in genotype 2 bovine viral diarrhea viruses”,Virus Research, vol. 79, pp. 59-69, (2001).
J.T. van Oirschot, et. al., “Vaccination of cattle against bovine viral diarrhoea”,Veterinary Microbiology, vol. 64, pp. 169-183, (1999).
Julia F. Ridpath, et. al., “Delayed Onset Postvaccinal Mucosal Disease as a Result of Genetic Recombination between Genotype 1 and Genotype 2 BVDV”,Virology, vol. 212, pp. 259-262, (1995).
Julia F. Ridpath, et. al., “Detection and Characterization of Genetic Recombination in Cytopathic Type 2 Bovine Viral Diarrhea Viruses”,Journal of Virology, vol. 74, No. 18, pp. 8771-8774, (2000).
{hacek over (S)}tefan Vil{hacek over (c)}ek, et. al., “Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates”,Veterinary Microbiology, vol. 77, pp. 129-136, (2000).
Li Wang, et. al., “Evolutionary implications of genetic variations in the S1 gene of infectious bronchitis virus”,Virus Research, vol. 34, pp. 327-338, (1994).
Michael Worobey, et. al., “Evolutionary aspects of recombination in RNA viruses”,Journal of General Virology, vol. 80, pp. 2535-2543, (1999).
Michael Worobey, et. al., “Widespread intra-serotype recombination in natural populations of dengue virus”,Proc. Natl. Acad. Sci. USA, vol. 96, pp. 7352-7357, (1999).
Ellsworth, MA, et al., “Efficacy of Bovi-Shield GOLD 5 vaccine against bovine viral diarrhea virus type 2 respiratory challenge,” Pfizer Animal Health Technical Bulletin, Nov. 2003, pp. 1-8.
Venugopal, K., et al., “Towards a new generation of flavivirus vaccines,” Butterworth Scientific, Guildford, GB, vol. 12, No. 11, Aug. 1994, pp. 966-975.
Widjojoatmodjo, MN, et al., “Classical Swine Fever Virus Erns Deletion Mutants: trans-Complementation and Potential Use as Nontransmissible, Modified, Live-Attenuated Marker Vaccines,” Journal of Virology, The American Society of Microbiology, vol. 74, No. 7, Apr. 2000, pp. 2973-2980.
Calvert Jay Gregory
Cao Xuemei
O'Hara Michael K.
Welch Siao-Kun Wan
Gumbleton Timothy J.
Mosher Mary E.
Pfizer Inc.
Pfizer Products Inc.
LandOfFree
Safe mutant viral vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Safe mutant viral vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Safe mutant viral vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3904717